Posted: 14 February 2024
Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that it has renewed its strategic partnership with Melbourne’s Hudson Institute of Medical Research for a further 12 months.
The partnership and in-licensed technology are key components of the company’s Sofra™ platform, via which Noxopharm is building a promising portfolio of assets including the SOFVAC™ mRNA vaccine enhancer and SOF-SKN™ topical skin medication for lupus and psoriasis.
Hudson Institute is a leading Australian medical research organisation recognised internationally for discovery science and translational research, and home to Australia’s largest group of inflammation and immunity scientists and clinicians. Among them is Associate Professor Michael Gantier, an expert in nucleic acids biology whose research is opening novel therapeutic avenues to dampen the inflammation that leads to autoimmune diseases.
The updated contract will see Noxopharm, A/Prof Gantier and the Hudson Institute team continue to develop the Sofra platform while increasing the company’s asset library. This will involve focusing not only on important inflammatory receptors like TL7 and TLR8, but also broadening the range of proprietary oligonucleotides that can be used to turn various other inflammatory receptors on or off as required.
Hudson Institute Director and CEO Professor Elizabeth Hartland said: “We are very pleased to be broadening and deepening our relationship with Noxopharm, especially at a time when interest in RNA-related technologies is higher than it has ever been. We strongly believe in long-term partnerships with trusted commercial partners like Noxopharm and are looking forward to seeing our work together develop as the year progresses.”
Noxopharm CEO Dr Gisela Mautner said: “In conjunction with the Hudson Institute team, we are making significant progress with our Sofra platform and advancing towards our goal of establishing Noxopharm as a leader in Australia in the RNA space. The commercial opportunities for us are considerable because the RNA market is expanding rapidly and will be sizeable in the future, and our ongoing strategic partnership is therefore a critical aspect of building shareholder value.”
As part of current initiatives to promote Sofra’s proprietary technology to key international audiences, Dr Mautner will be speaking at the RNA Leaders Europe Conference in Switzerland in March.
